The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Stericycle's revenues will grow 10.0% and EPS will increase 13.2%.
The average estimate for revenue is $491.1 million. On the bottom line, the average EPS estimate is $0.86.
Last quarter, Stericycle booked revenue of $480.5 million. GAAP reported sales were 14% higher than the prior-year quarter's $420.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.84. GAAP EPS of $0.75 for Q3 were 10% higher than the prior-year quarter's $0.68 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 47.2%, 40 basis points worse than the prior-year quarter. Operating margin was 25.1%, 110 basis points worse than the prior-year quarter. Net margin was 13.6%, 50 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $1.90 billion. The average EPS estimate is $3.28.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 297 members out of 321 rating the stock outperform, and 24 members rating it underperform. Among 102 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 95 give Stericycle a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Stericycle is outperform, with an average price target of $97.50.
The rich are different than you and me: They might not notice the moneymaking stories right under our noses. In our new report, "Middle-Class Millionaire-Makers: 3 Stocks Wall Street's Too Rich to Notice," we give you three Peter Lynch-inspired buy-what-you-know stocks for the 99%. Click here for instant access to this free report.
- Add Stericycle to My Watchlist.